Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin

Expert Opinion on Drug Delivery

Volumn 9, Issue 11, 2012, Pages 1347-1364

  Mohanty, Chandana ^a   Das, Manasi ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Absorption; Bioavailability; Curcumin; Metabolism; Nanocarrirer; Poor solubility

Indexed keywords

CURCUMIN; DEMETHOXYCURCUMIN; DENDRIMER; DRUG ANALOG; GENUC DERUM CURCIMIN; LIPOSOME; N CURCUMIN; NANOCARRIER; NANOCURCUMINOIDS; NANOSUSPENSION; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE; THERACURCUMIN; UNCLASSIFIED DRUG;

ARTICLE; DEGRADATION KINETICS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG ISOLATION; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; HYDROGEL; MAGNET; MICELLE; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN;

ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; SOLUBILITY;

EID: 84867782202     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.724676     Document Type: Article

References (132)

1. Basnet P, Skalko-Basnet N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011;16:4567-98
2. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005;41:1955-68 (Pubitemid 41557681)
3. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007;28:1765-73 (Pubitemid 47289040)
4. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-90 (Pubitemid 40719616)
5. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40-59
6. Maheshwari RK, Singh AK, Gaddipati J, et al. Multiple biological activities of curcumin: A short review. Life Sci 2006;78:2081-7
7. Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011;28:1937-55
8. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011;12:332-47
9. Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol 2007;595:269-300
10. Lao CD, Ruffin MTt, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10
11. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4:807-18
12. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010;31:6597-611
13. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-9
14. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978;43:86-92 (Pubitemid 9016316)
15. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6 (Pubitemid 28234275)
16. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008;76:1590-611
17. Kundu P, Mohanty C, Sahoo SK. Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 2012;8:2670-87
18. Ma Z, Haddadi A, Molavi O, et al. Micelles of poly(ethylene oxide)-b-poly (epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008; 86:300-10 (Pubitemid 351969628)
19. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS ONE 2012;7:e32616
20. Mohanty C, Acharya S, Mohanty AK, et al. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond) 2010;5:433-49
21. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine 2007;3:20-31 (Pubitemid 46428187)
22. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003;8:1112-20 (Pubitemid 37547917)
23. Mohanty C, Das M, Kanwar JR, et al. Receptor mediated tumor targeting: An emerging approach for cancer therapy. Curr Drug Deliv 2011;8:45-58
24. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009;6:285-304
25. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov Today 2012;17:71-80
26. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 2007;130:769-74 (Pubitemid 47332575)
27. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-2 (Pubitemid 38541921)
28. Cartiera MS, Ferreira EC, Caputo C, et al. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm 2010;7:86-93
29. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009;15:2087-94
30. Taylor RA, Leonard MC. Curcumin for inflammatory bowel disease: A review of human studies. Altern Med Rev 2011;16:152-6
31. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 2005;50:2191-3 (Pubitemid 41504112)
32. Dikshit M, Rastogi L, Shukla R, et al. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Indian J Med Res 1995;101:31-5
33. Huang HC, Jan TR, Yeh SF. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 1992;221:381-4
34. Manikandan P, Sumitra M, Aishwarya S, et al. Curcumin modulates free radical quenching in myocardial ischaemia in rats. Int J Biochem Cell Biol 2004;36:1967-80
35. Chen WF, Deng SL, Zhou B, et al. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic Biol Med 2006;40:526-35 (Pubitemid 43139688)
36. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212
37. Gadad BS, Subramanya PK, Pullabhatla S, et al. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits alpha-synuclein oligomer formation: relevance to Parkinson's disease. Curr Pharm Des 2012;18:76-84
38. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
39. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-7 (Pubitemid 33051435)
40. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 2005;28:937-9 (Pubitemid 40740674)
41. Babu PS, Srinivasan K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 1995;152:13-21
42. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002;57:41-52 (Pubitemid 34128408)
43. Suryanarayana P, Saraswat M, Mrudula T, et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 2005;46:2092-9
44. Tourkina E, Gooz P, Oates JC, et al. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 2004;31:28-35 (Pubitemid 38888036)
45. Aggarwal S, Ichikawa H, Takada Y, et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006;69:195-206 (Pubitemid 43048906)
46. Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS ONE 2012;7:e32920
47. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003;23:363-98 (Pubitemid 36361976)
48. Das M, Dilnawaz F, Sahoo SK. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy. Nanomedicine (Lond) 2011;6:489-507
49. Das M, Sahoo SK. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Acta Biomater 2011;7:355-69
50. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D,Llactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011;8:852-66
51. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94
52. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002;244:127-35 (Pubitemid 35245453)
53. Souza CRA, Osme SF, Gloria MBA. Stability of curcuminoid pigments in model systems. J Food Process Preserv 1997;21:353-63 (Pubitemid 127358855)
54. Lin JK, Pan MH, Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000;13:153-8
55. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997;15:1867-76
56. Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007;60:171-7 (Pubitemid 46742531)
57. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11 (Pubitemid 34118319)
58. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 1981;20:251-7 (Pubitemid 11117911)
59. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978;8:761-8 (Pubitemid 9119050)
60. Pfeiffer E, Hoehle SI, Walch SG, et al. Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem 2007;55:538-44 (Pubitemid 46586343)
61. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010;79:330-8
62. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999;27:486-94
63. Antony B. A composition to enhance the bioavailability of curcumin. US 2007/0148263 A1 (2007)
64. Antony B, Merina B, Iyer V, et al. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95-CG (Biocurcumax-), A Novel Bioenhanced Preparation of Curcumin. Indian J Pharm Sci 2008;70:445-9
65. Shen L, Ji HF. Theoretical study on physicochemical properties of curcumin. Spectrochim Acta A Mol Biomol Spectrosc 2007;67:619-23 (Pubitemid 46809631)
66. Barthelemy S, Vergnes L, Moynier M, et al. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol 1998;149:43-52 (Pubitemid 28162429)
67. Kumar S, Dubey KK, Tripathi S, et al. Design and synthesis of curcumin-bioconjugates to improve systemic delivery. Nucleic Acids Symp Ser 2000;(44):75-6
68. Mishra S, Kapoor N, Mubarak Ali A, et al. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med 2005;38:1353-60 (Pubitemid 40602837)
69. Mishra S, Karmodiya K, Surolia N, et al. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem 2008;16:2894-902 (Pubitemid 351418213)
70. Tong QS, Zheng LD, Lu P, et al. Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anticancer Drugs 2006;17:279-87
71. Pana Y, Zhub G, Wanga Y, et al. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 2012; Epub ahead of print
72. Wu A, Ying Z, Schubert D, et al. Brain and spinal cord interaction: A dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. Neurorehabil Neural Repair 2011;25:332-42
73. Kim DC, Ku SK, Lee W, et al. Barrier protective activities of curcumin and its derivative. Inflamm Res 2012;61:437-44
74. Fiala M, Liu PT, Espinosa-Jeffrey A, et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 2007;104:12849-54 (Pubitemid 47255243)
75. Dairam A, Limson JL, Watkins GM, et al. Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. J Agric Food Chem 2007;55:1039-44
76. Kiuchi F, Goto Y, Sugimoto N, et al. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull (Tokyo) 1993;41:1640-3 (Pubitemid 23326798)
77. Simon A, Allais DP, Duroux JL, et al. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 1998;129:111-16 (Pubitemid 28375245)
78. Ferrari E, Lazzari S, Marverti G, et al. Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. Bioorg Med Chem 2009;17:3043-52
79. Liang G, Shao L, Wang Y, et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 2009;17:2623-31
80. Shibata H, Yamakoshi H, Sato A, et al. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 2009;100:956-60
81. Mosley CA, Liotta DC, Snyder JP. Highly active anticancer curcumin analogues. Adv Exp Med Biol 2007;595:77-103
82. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat 2011;128:97-107
83. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov Today 2010;15:842-50
84. Martins S, Sarmento B, Ferreira DC, et al. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 2007;2:595-607
85. Souto EB, Muller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010(197):115-41
86. Souto EB. A special issue on Lipid-based delivery systems (liposomes, lipid nanoparticles, lipid matrices and medicines). J Biomed Nanotechnol 2009;5:315-16
87. Kakkar V, Singh S, Singla D, et al. Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:3427-31
88. Nandakumar DN, Nagaraj VA, Vathsala PG, et al. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemother 2006;50:1859-60
89. Mishra K, Dash AP, Swain BK, et al. Anti-malarial activities of Andrographis paniculata and Hedyotis corymbosa extracts and their combination with curcumin. Malar J 2009;8:26
90. Nayak AP, Tiyaboonchai W, Patankar S, et al. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010;81:263-73
91. Chavhan SS, Petkar KC, Sawant KK. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects. Crit Rev Ther Drug Carrier Syst 2011;28:447-88
92. Barrett E. Nanosuspensions in drug delivery. Nature Reviews Drug Discovery 2004;3:785-96
93. Liversidge G, Cundy K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125:91-7
94. Gao Y, Li Z, Sun M, et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 2011;18:131-42
95. Solans C, Izquierdo P, Nolla J, et al. Nano-emulsions. Curr Opin Colloid Interface Sci 2005;10:102-10 (Pubitemid 41565542)
96. Huang Q, Yu H, Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci 2011;75:R50-7
97. Onoue S, Takahashi H, Kawabata Y, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci 2010;99:1871-81
98. Lin W, Hong JL, Shen G, et al. Pharmacokinetics of dietary cancer chemopreventive compound dibenzoylmethane in rats and the impact of nanoemulsion and genetic knockout of Nrf2 on its disposition. Biopharm Drug Dispos 2010;32:65-75
99. Yu H, Huang Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem 2012;60:5373-9
100. Yeshaswi M, Srinivas P, Sadanandam M. Novel hydrogels and their drug delivery strategies : A review. Int J Drug Formulation Res 2010;1:166-203
101. Dandekar PP, Jain R, Patil S, et al. Curcumin-loaded hydrogel nanoparticles: Application in anti-malarial therapy and toxicological evaluation. J Pharm Sci 2010;99:4992-5010
102. Yanyu X, Yunmei S, Zhipeng C, et al. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm 2006;307:77-82 (Pubitemid 41773254)
103. Sharma A, Gupta NK, Dixit VK. Complexation with phosphatidyl choline as a strategy for absorption enhancement of boswellic acid. Drug Deliv 2010;17:587-95
104. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci 2011;100:1987-95
105. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011;74:664-9
106. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2011;17:160-6
107. Li R, Qiao X, Li Q, et al. Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2751-8
108. Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994;7:463-8
109. Agashe H, Sahoo K, Lagisetty P, et al. Cyclodextrin-mediated entrapment of curcuminoid 4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2- butenoic acid] or CLEFMA in liposomes for treatment of xenograft lung tumor in rats. Colloids Surf B Biointerfaces 2011;84:329-37
110. Lan L, Fadi S, Razelle K. Liposome-encapsulated curcumin. Cancer Chemother Pharmacol 2005;104:1322-31
111. Wang D, Veena MS, Stevenson K, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008;14:6228-36
112. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnol 2007;5:3
113. Bisht S, Mizuma M, Feldmann G, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 2010;9:2255-64
114. Ma Z, Shayeganpour A, Brocks DR, et al. High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 2007;21:546-52 (Pubitemid 46736190)
115. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011;354:116-23
116. Abderrezak A, Bourassa P, Mandeville JS, et al. Dendrimers bind antioxidant polyphenols and cisplatin drug. PLoS One 2012;7:e33102
117. Shi W, Dolai S, Rizk S, et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett 2007;9:5461-4
118. Suwannateep N, Banlunara W, Wanichwecharungruang SP, et al. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 2011;151:176-82
119. Mazzarino L, Silva LF, Curta JC, et al. Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: An in vitro and In vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study. J Biomed Nanotechnol 2011;7:406-14
120. Dilnawaz F, Singh A, Sahoo SK. Transferrin-conjugated curcumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater 2012;8:704-19
121. Yallapu MM, Othman SF, Curtis ET, et al. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine 2012;7:1761-79
122. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, et al. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm 2010;76:475-85
123. Yadav VR, Prasad S, Kannappan R, et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 2010;80:1021-32
124. Seo SW, Han HK, Chun MK, et al. Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol(R) HS15 as a carrier. Int J Pharm 2012;424:18-25
125. Chin SF, Iyer KS, Saunders M, et al. Encapsulation and sustained release of curcumin using superparamagnetic silica reservoirs. Chemistry (Easton) 2009;15:5661-5
126. Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012;69:65-70
127. Kostarelos K. The long and short of carbon nanotube toxicity. Nat Biotechnol 2008;26:774-6 (Pubitemid 351961446)
128. Lam CW, James JT, McCluskey R, et al. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit Rev Toxicol 2006;36:189-217
129. Pandey MK, Kumar S, Thimmulappa RK, et al. Design, synthesis and evaluation of novel PEGylated curcumin analogs as potent Nrf2 activators in human bronchial epithelial cells. Eur J Pharm Sci 2011;43:16-24
130. Lim KJ, Bisht S, Bar EE, et al. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011;11:464-73
131. Doggui S, Sahni JK, Arseneault M, et al. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 2012;30:377-92
132. Acharya S, Sahoo SK. Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy. Biomaterials 2012;32:5643-62